Introduction: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis evaluated the Summit Lab Score for validation as a predictor of the first episode of moderate-to-severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other outcomes, in patients with COPD and high arterial pulse wave velocity (aPWV).
Methods: Data from a multicenter, randomized, placebo-controlled, double-blind study were retrospectively analyzed to evaluate treatment effects of once-daily fluticasone furoate/vilanterol 100/25 μg in patients with COPD and an elevated CV risk (aPWV≥11m/s) over 24 weeks. The previously derived Summit Lab Score and, secondarily, the Intermountain Risk Score (IMRS) were computed for each patient, with patients then stratified into tertiles for each score. Risk of moderate-to-severe AECOPD was analyzed across tertiles using Kaplan-Meier survival curve and Cox regression analyses.
Results: In 430 patients with COPD, Kaplan-Meier probabilities of no moderate-to-severe AECOPD for Summit Lab Score tertiles 1, 2, and 3 were 92.3%, 95.5%, and 85.1%, respectively ( trend = 0.015), over 24 weeks. Grouped by IMRS tertiles, the respective probabilities were 92.9%, 91.2%, and 88.3%, respectively ( trend = 0.141). Length of stay in the hospital ( = 0.034) and the hospital ward ( = 0.042) were also significantly different between Summit Lab Score tertiles but not for intensive care ( = 0.191).
Conclusion: The Summit Lab Score was associated with the 24-week risk of moderate-to-severe AECOPD in COPD patients with elevated CV risk. Secondarily, IMRS showed a trend towards differences in the risk of AECOPD, which was not statistically significant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802087 | PMC |
| http://dx.doi.org/10.2147/COPD.S279645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
Lung Cancer
January 2025
Lung Cancer Clinic, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy. However, many unanswered questions and challenges remain, including the application of clinical trial data to routine clinical practice. Recognising the unique demographic profile of Asian patients with NSCLC and heterogeneous healthcare systems, the Asian Thoracic Oncology Research Group (ATORG) convened a consensus meeting in Singapore on 26 April 2024 to discuss relevant issues spanning diagnostic testing to post-neoadjuvant treatment considerations and future directions.
View Article and Find Full Text PDFLeptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
J Thorac Oncol
January 2025
Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, People's Republic of China.
Consensus on the lung cancer management after third-generation EGFR-TKI resistance.
Lancet Reg Health West Pac
December 2024
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Article Synopsis
- Lung cancer is the most common type of cancer in the Asia-Pacific region, with non-small cell lung cancer (NSCLC) making up about 85% of cases, and a significant mutation rate of 40-60% in Asian patients with lung adenocarcinoma.
- Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved treatment for NSCLC with mutations, but managing resistance to these drugs is still a major issue with no standardized guidelines.
- A set of recommendations has been developed, integrating international guidelines and regional clinical experiences, to help healthcare providers classify resistance, conduct clinical testing, and devise treatment strategies for patients struggling with resistance to third-generation EGFR-TKIs.
Dynamic human gut microbiome and immune shifts during an immersive psychosocial intervention program.
Brain Behav Immun
December 2024
Department of Genetics, Stanford University School of Medicine, CA, USA; Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine, CA, USA; Stanford Healthcare Innovation Lab, Stanford University, CA, USA. Electronic address:
Background: Although depression is a leading cause of disability worldwide, the pathophysiological mechanisms underlying this disorder-particularly those involving the gut microbiome-are poorly understood.
Method: To investigate, we conducted a community-based observational study to explore complex associations between changes in the gut microbiome, cytokine levels, and depression symptoms in 52 participants (M = 49.56, SD = 13.
Introduction to Generative Artificial Intelligence: Contextualizing the Future.
Arch Pathol Lab Med
December 2024
the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Seheult, Pritt).
Context.—: Generative artificial intelligence (GAI) is a promising new technology with the potential to transform communication and workflows in health care and pathology. Although new technologies offer advantages, they also come with risks that users, particularly early adopters, must recognize.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!